CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.
To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this link and request a return call. The Call me™ passcode is 9270590. The audio webcast can be accessed live on this link or on the “Events and Presentations” page under the “Investor Relations” tab of the Spero Corporate Website at https://sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information, visit www.sperotherapeutics.com
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.75 |
| Daily Change: | 0.01 1.89 |
| Daily Volume: | 38,326 |
| Market Cap: | US$41.110M |
March 27, 2025 January 10, 2025 November 14, 2024 October 29, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
